Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Raises Double Digit $ Millions in Series A Round for Microarray-Based Cancer Tests

This story has been updated from an earlier version to include more precise funding information from Agendia.

 

NEW YORK, GenomeWeb News (March 30) - Dutch cancer diagnostics company Agendia has raised "double digit" millions of dollars in a Series A financing round, the company told GenomeWeb News today.

 

Agendia will use the funding to market its microarray-based breast cancer test, which it launched earlier this year, and to develop similar gene expression-based tests for other cancers.

 

Investors included Gilde Investment Management, which led the round, as well as Global Life Science Ventures and Axa Private Equity Funds.

 

Agendia, based in Amsterdam, the Netherlands, was founded in 2003 by scientists from the Netherlands Cancer Institute who developed a microarray-based test to predict the aggressiveness of breast cancer tumors.

 

Bas van der Baan, Agendia's director of business development, told GenomeWeb News that the company is seeking to in-license additional expression profiles for cancer and other diseases. Also, Agendia plans to launch new expression-based tests within 12 months. 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.